Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (441-450 of 527) with videos related to

Pageof 53
Sort By:
Cancer Medicine|November 17, 2021
Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levelsPo-Yao Hsu, Tzu-Sheng Cheng, Shih-Chang Chuang, et al.
Nature Communications|August 29, 2024
An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infectionAtish Mukherji, Frank Jühling, Yogy Simanjuntak, et al.
Clinical and Molecular Hepatology|October 4, 2023
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseasesPin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2021
A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver DiseaseZobair M Younossi, Janus P Ong, Hirokazu Takahashi, et al.
The Lancet. Gastroenterology & Hepatology|February 6, 2025
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trialYoung-Suk Lim, Ming-Lung Yu, Jonggi Choi, et al.
Gut|June 4, 2025
Differential HCC risk among HBV indeterminate types at baseline and by phase transitionRui Huang, Huy N Trinh, Satoshi Yasuda, et al.
Scientific Reports|April 21, 2021
Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in TaiwanMing-Ying Lu, Chun-Ting Chen, Yu-Lueng Shih, et al.
Hepatology Communications|January 13, 2021
Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular CarcinomaVincent L Chen, Ming-Lun Yeh, Ju Dong Yang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 12, 2021
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) RegistryZobair M Younossi, Yusuf Yilmaz, Ming-Lung Yu, et al.
The Journal of Infectious Diseases|May 17, 2021
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis BYao-Chun Hsu, Ming-Lun Yeh, Grace Lai-Hung Wong, et al.
Pageof 53

Showing results (441-450 of 527) with videos related to

Sort By:
Pageof 53
Cancer Medicine|November 17, 2021
Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levelsPo-Yao Hsu, Tzu-Sheng Cheng, Shih-Chang Chuang, et al.
Nature Communications|August 29, 2024
An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infectionAtish Mukherji, Frank Jühling, Yogy Simanjuntak, et al.
Clinical and Molecular Hepatology|October 4, 2023
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseasesPin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2021
A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver DiseaseZobair M Younossi, Janus P Ong, Hirokazu Takahashi, et al.
The Lancet. Gastroenterology & Hepatology|February 6, 2025
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trialYoung-Suk Lim, Ming-Lung Yu, Jonggi Choi, et al.
Gut|June 4, 2025
Differential HCC risk among HBV indeterminate types at baseline and by phase transitionRui Huang, Huy N Trinh, Satoshi Yasuda, et al.
Scientific Reports|April 21, 2021
Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in TaiwanMing-Ying Lu, Chun-Ting Chen, Yu-Lueng Shih, et al.
Hepatology Communications|January 13, 2021
Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular CarcinomaVincent L Chen, Ming-Lun Yeh, Ju Dong Yang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 12, 2021
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) RegistryZobair M Younossi, Yusuf Yilmaz, Ming-Lung Yu, et al.
The Journal of Infectious Diseases|May 17, 2021
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis BYao-Chun Hsu, Ming-Lun Yeh, Grace Lai-Hung Wong, et al.
Pageof 53